Fmr LLC Has $583.24 Million Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

FMR LLC grew its holdings in Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) by 0.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 49,301,583 shares of the company's stock after acquiring an additional 156,527 shares during the period. FMR LLC owned 6.77% of Roivant Sciences worth $583,238,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of the business. Nordea Investment Management AB increased its position in Roivant Sciences by 22.5% during the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company's stock worth $3,306,000 after buying an additional 52,031 shares during the last quarter. Barclays PLC raised its stake in shares of Roivant Sciences by 19.7% in the 3rd quarter. Barclays PLC now owns 459,521 shares of the company's stock valued at $5,302,000 after acquiring an additional 75,609 shares in the last quarter. Retirement Systems of Alabama lifted its holdings in Roivant Sciences by 26.9% in the 3rd quarter. Retirement Systems of Alabama now owns 530,022 shares of the company's stock worth $6,116,000 after purchasing an additional 112,286 shares during the last quarter. Elevate Capital Advisors LLC bought a new stake in Roivant Sciences during the fourth quarter worth approximately $2,116,000. Finally, State Street Corp grew its holdings in Roivant Sciences by 6.1% during the third quarter. State Street Corp now owns 19,561,249 shares of the company's stock valued at $225,737,000 after purchasing an additional 1,118,561 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company's stock.

Remove Ads

Insider Buying and Selling at Roivant Sciences

In other Roivant Sciences news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $10.43, for a total value of $2,372,825.00. Following the transaction, the chief accounting officer now directly owns 163,264 shares in the company, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, COO Eric Venker sold 434,478 shares of the firm's stock in a transaction dated Monday, March 24th. The shares were sold at an average price of $10.82, for a total value of $4,701,051.96. Following the completion of the transaction, the chief operating officer now owns 1,127,290 shares in the company, valued at approximately $12,197,277.80. This represents a 27.82 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock worth $15,028,538 over the last ninety days. Corporate insiders own 7.90% of the company's stock.

Roivant Sciences Price Performance

ROIV stock traded up $0.24 on Monday, reaching $10.10. 735,150 shares of the company were exchanged, compared to its average volume of 5,379,617. The firm has a market capitalization of $7.21 billion, a PE ratio of -67.33 and a beta of 1.25. The stock's fifty day moving average price is $10.40 and its 200 day moving average price is $11.22. Roivant Sciences Ltd. has a 12 month low of $8.73 and a 12 month high of $13.06.

Roivant Sciences (NASDAQ:ROIV - Get Free Report) last announced its quarterly earnings data on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. As a group, research analysts expect that Roivant Sciences Ltd. will post -0.92 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Cantor Fitzgerald upgraded shares of Roivant Sciences to a "strong-buy" rating in a research note on Tuesday, March 4th. HC Wainwright restated a "buy" rating and set a $18.00 price target on shares of Roivant Sciences in a report on Tuesday, February 11th.

Roivant Sciences Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.